Download key takeaways

Accelerating Drug Development: Proteomics in Clinical Trials

The conversation tackled a key question in today’s research landscape:

How are leading biopharma teams using proteomics to accelerate decisions, de-risk development, and get closer to the patient?

In this panel discussion, biopharma innovators share real examples of how the SomaScan™ Assay is being used to accelerate decision making, de-risk development, and bring clinical insights closer to the patient. From identifying early signals of efficacy to uncovering why a drug failed, panelists discuss how proteomic data is helping teams understand trial outcomes earlier and with greater confidence.